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Abstract
Liver cirrhosis is associated with a wide range of systemic and pulmonary vascular 
abnormalities. Cardiac dysfunction also occurs in patients with advanced liver disease 
(cirrhotic cardiomyopathy). The circulation in cirrhosis is hyperdynamic, which is typi-
cally characterized by hypotension resulting from the associated vasodilatation and 
reflex tachycardia. The circulatory dysfunction in cirrhosis is the proposed pathophysi-
ological mechanism leading to sodium and water retention in patients with liver cirrho-
sis. Hyperdynamic circulation is triggered by increased intrahepatic resistance due to 
cirrhosis, leading to a progressive increase in portal venous pressure. As portal hyperten-
sion worsens, local production of vasodilators increases due to endothelial activation, 
leading to splanchnic and systemic arterial vasodilation. Nitric oxide (NO) is considered 
one of the most important vasodilator molecules in the splanchnic and systemic circu-
lation. The reduction in the effective arterial blood volume results in diminished renal 
arterial blood flow and subsequently triggers the rennin-angiotensin-aldosterone system 
(RAAS), antidiuretic hormones (ADHs) and sympathetic nervous system (SNS), leading 
to renal artery vasoconstriction. All these changes lead to sodium retention and volume 
expansion, manifested as ascites and peripheral edema. Furthermore, disease progres-
sion is associated with various degrees of renal dysfunction.
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1. Introduction
Liver cirrhosis is associated with a wide range of systemic and pulmonary vascular abnor-
malities. Cardiac dysfunction has also been described in patients with advanced liver dis-
ease (cirrhotic cardiomyopathy) [1–4]. The circulation in cirrhosis has been described as being 
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hyperdynamic, which is typically characterized by hypotension resulting from the associated 
vasodilatation and reflex tachycardia. These cardiovascular abnormalities play a major role 
in the pathogenesis of multiple life-threatening complications, including ascites, spontane-
ous bacterial peritonitis, hepatorenal syndrome (HRS), esophageal varices and pulmonary 
related complications [5, 6]. The hyperdynamic circulation is triggered by increased intrahe-
patic resistance due to cirrhosis, leading to a progressive increase in portal venous pressure 
[7, 8]. As portal hypertension worsens, there is an increased local production of vasodilators 
due to endothelial activation, leading to splanchnic and systemic arterial vasodilation. Nitric 
oxide (NO) is thought to be one of the most important vasodilator molecules in the splanch-
nic and systemic circulation. NO is overproduced in cirrhosis; measured serum levels are 
significantly elevated in both cirrhotic patients and in animal models [9–11]. The reduction 
in the effective arterial blood volume results in diminished renal arterial blood flow and sub-
sequently triggers the rennin-angiotensin-aldosterone system (RAAS), antidiuretic hormone 
(ADH) and sympathetic nervous system (SNS), leading to renal artery vasoconstriction. All 
these changes lead to sodium retention and volume expansion, manifested as ascites and 
peripheral edema. Furthermore, advanced liver disease is usually associated with various 
degrees of renal dysfunction. In cirrhotic patients with hepatorenal syndrome (HRS), renal 
plasma flow and glomerular filtration rate (GFR) are significantly diminished and may reach 
levels similar to those seen in patients with advanced renal disease [12, 13]. Sodium retention 
usually occurs in association with the inability to excrete a normal water load, resulting in 
increased total body water and dilutional hyponatremia [14, 15]. However, unlike the situa-
tion of end-stage renal disease, no significant histological abnormality is present within the 
kidneys of patients with HRS, and the process is reversible after liver transplantation (LT) 
[16]. The aim of this chapter is to discuss the impact of portal hypertension on the cardiovas-
cular system in cirrhosis, with special emphasis on the pathogenesis of ascites.
2. Ascites
The peritoneum is a serous membrane made up of visceral and parietal layers. The pari-
etal peritoneum lines the coelomic cavity, and the visceral layer of the peritoneum lines the 
surface of organs. The peritoneal cavity is an empty space between the visceral and parietal 
layers of the peritoneum. The potential space of the peritoneal cavity is normally not visible 
on imaging as it contains only a small amount of fluid (approximately 100 mL). The fluid 
is mostly water with electrolytes, antibodies, white blood cells, albumin, glucose and other 
biochemicals [17]. Its main function is to reduce the friction between the abdominal organs 
as they move around during digestion. The word ascites is derived from the Greek word 
“askos,” which means a bag or sack and is defined as pathological fluid accumulation within 
the peritoneal cavity. Ascites is a frequent complication of cirrhosis and portal hypertension 
because of the increase of the sinusoidal hydrostatic pressure. Cirrhosis accounts for over 
75% of episodes of ascites, with all other causes accounting for less than 25% (Table 1) [18]. 
Ascites has been associated with increased morbidity and mortality, with liver transplant-free 
mortality rates ranging from 15 to 20% at 1 year to nearly 50–60% at 5 years from the time of 
diagnosis [19, 20].
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3. The heart (cirrhotic cardiomyopathy)
In 1953, Kowalski and Abelmann described an abnormal circulatory pattern in a group of 
cirrhotic patients. The examined the circulation in 22 alcoholic cirrhotic patients and con-
cluded that these patients had a large stroke volume, prolonged Q-T interval and reduced 
peripheral vascular resistance. They were some of the first researchers to question the impact 
of liver disease on the heart [21]. These findings were then confirmed in multiple experi-
mental models of portal hypertension and in patients with cirrhosis. Initially, it was thought 
that these circulatory manifestations were secondary to alcoholic-related malnutrition; how-
ever, future studies confirmed the same circulatory dysregulation in cirrhotic patients with 
various underlying etiologies [1–4]. In the absence of known cardiac disease, the diagnos-
tic criteria for cirrhotic cardiomyopathy rest on the presence of an attenuated systolic or 
diastolic response to stressful stimuli and are supported by the presence of structural or 
histological changes in cardiac chambers, electrophysiological abnormalities and elevation 
in serum markers suggestive of cardiac stress [22]. In addition to abnormal systolic dys-
function, cirrhotic patients also clearly demonstrate abnormal diastolic dysfunction, espe-
cially in patients with ascites, and it has been shown that paracentesis can improve diastolic 
dysfunction. Left ventricular (LV) diastolic dysfunction manifests as impaired LV relaxation 
secondary to LV wall stiffness, which results in the increase in filling pressure. Glenn et al. 
investigated the role of passive tension regulators—titin and collagen—in the pathogenesis 
of cirrhotic diastolic dysfunction. They showed that alterations in titin modulation, PKA lev-
els, and collagen configuration contributed to the pathogenesis of this condition [23]. Velocity 
of blood flow from the left atrium to the left ventricle during early (E wave) and late (A wave) 
phases of diastole can help in assessing diastolic function. A low E/A ratio indicates a non-
compliant ventricle [24]. This finding was also confirmed in other studies [25, 26]. Multiple 
factors affecting cardiac cell function have been implicated in the pathogenesis of cirrhotic 











Table 1. Causes of ascites.
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impacts cardiac contractility [27]; (b) Reduction in the cardiac cell membrane fluidity, which 
impairs the function of membrane-bound ion channels, alters control of vascular tone and 
reduces the β-adrenoceptor function [28, 29]; (c) Reduced muscarinic receptor activity, which 
has a negative inotropic effect on the heart [30]; (d) Augmented nitric oxide activity, which 
negatively impacts cardiac contractility [31, 32]; (e) Carbon monoxide (CO) and endocannab-
inoid activity negatively impacts cardiac contractility in cirrhotic patients [33–35]. Multiple 
other studies have demonstrated significant structural cardiac abnormalities in all cardiac 
chambers of cirrhotic patients [36].
4. Systemic and splanchnic circulation
Portosystemic collaterals are formed secondary to cirrhosis-induced portal hypertension, 
which allows gut-derived humoral substances to directly enter systemic circulation without 
detoxification by the liver. Arterial vasodilatation in portal hypertension results from the pre-
dominant production of various vasodilators [37]. NO is thought to be the major vasodilator 
molecule in cirrhotic patients. The intrahepatic microcirculation is altered significantly in 
liver cirrhosis, secondary to both architectural and vasoactive humoral changes, resulting 
in an increase in vasoactive molecules associated with a decrease in intrahepatic NO pro-
duction [38, 39]. On the other hand, multiple studies have documented an elevated serum 
level of NO in the systemic and splanchnic circulation in both cirrhotic patients and in ani-
mal models [40–43]. NO is an endothelial-derived relaxing factor that leads to systemic arte-
rial vasodilatation. Three isoforms of NO synthase (NOS) have been described: endothelial 
(eNOS), inducible (iNOS), and neuronal (nNOS). However, the leading isoform contributing 
to these vascular changes remains obscure [44]. Ferguson and colleagues were the first group 
to use a highly selective iNOS inhibitor to evaluate the role iNOS in the regulation of vascular 
tone in patients with ascites. Forearm blood flow was measured in eight patients with asci-
tes and was compared with eight matched healthy volunteers, during intrabrachial infusion 
of 1400 W (0.1–1 μmol/min), NG-monomethyl-L-arginine (L-NMMA, a non-selective NOS 
inhibitor; 2–8 μmol), and norepinephrine. They showed that iNOS inhibitor causes systemic 
vasoconstriction in patients with ascites only. This supports the role of iNOS in the circula-
tory changes associated with cirrhosis [45]. One major factor that plays an important role in 
promoting NO production is the altered intestinal permeability in patients with advanced 
liver disease. As a result various endotoxins cross the intestine to the systemic circulation 
and stimulate the production of NO [46, 47]. TNF-α is also considered to be a NO inducers. 
Inhibition of TNF-α production resulted in improvement in the hyperdynamic circulation 
in various animal model studies [48, 49]. Endocannabinoids have also been implicated in 
the peripheral vasodilatation of cirrhosis. Activation of endothelial cannabinoid receptors 
by the endogenously produced endocannabinoids causes pronounced vasodilatation in cir-
rhotic rats [50, 51]. Interestingly, multiple studies have shown a potentially important role 
of the central nervous system (CNS) in the pathogenesis of the portal hypertension-induced 
hyperdynamic circulation. The cardiovascular system is controlled by neural influences that 
include the central nervous system (CNS) and peripheral afferent and efferent nerves. Portal 
hypertension activates receptors in the mesenteric area; the signals are relayed to central 
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cardiovascular-regulatory nuclei via afferent nerves. These nuclei then process the inputs 
and send out signals to the cardiovascular system through efferent pathways, leading to car-
diovascular changes [52]. Li and colleagues demonstrated that neonatal capsaicin denerva-
tion in rats prevented the development of hyperdynamic circulation and renal dysfunction 
as well as ascites formation in cirrhosis. These results indicate that intact primary afferent 
innervation is necessary for the development of hyperdynamic circulation and ascites forma-
tion [53]. A recent study revealed reversal of the cirrhosis associated vascular dysregulation 
after afferent denervation in an animal model. Portal vein ligation in cirrhotic rats activates 
a marker protein in the brain stem indicating CNS activation. Furthermore, blocking CNS 
Fos expression in cirrhotic rats resulted in eliminating the development of the hyperdynamic 
circulation [54]. The various potential pathogenic mechanisms leading to cardiovascular dis-
turbance and fluid retention are summarized in Table 2.
5. The lymphatic system
The lymphatic vascular system plays a critical role in ascites formation [55]. Lymphatic ves-
sels remove fluid from the interstitial fluid from various parts of the body and drain it into 
the blood stream. In healthy adult individuals, the lymphatic system returns as much as 
eight liters of interstitial fluid with 20–30 g of protein per liter to venous circulation every 
day. Any disturbance to this process leads to fluid accumulation, manifested as edema 
and ascites [55–58]. As with systemic and splanchnic circulation, the lymphatic system is 
also influenced by nitric oxide, leading to vasodilatation [59]. The development of portal 
Pathogenic mechanisms Cardiovascular effect
Down regulation of β-adrenergic receptors Decreases cardiac contractility
Reduction in the cardiac cell membrane fluidity Alters control of vascular tone and reduces the 
β-adrenoceptor function
Reduced muscarinic receptor activity Negative inotropic effect on the heart
Augmented nitric oxide activity Decreases cardiac contractility
Carbon monoxide Decreases cardiac contractility
Endocannabinoid activity Decreases cardiac contractility
Portosystemic collaterals This allows gut-derived humoral substances to 
directly enter the systemic circulation augmenting the 
hyperdynamic circulation
Systemic nitric oxide Systemic vasodilatation
Central nervous system-gut-axis Denervation prevents the development of 
hyperdynamic circulation and ascites formation
Activation of renin-angiotensin aldosterone system, 
sympathetic nervous system and nonosmotic release of 
antidiuretic hormone
Restores the normal hemodynamics in the setting of a 
hyperdynamic circulation through sodium and water 
retention
Table 2. Pathogenic mechanisms of cardiovascular disturbance in cirrhotic patients.
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hypertension in cirrhosis is associated with an increase in portal lymph flow. Normally, the 
liver produces a large amount of lymph, which is estimated to be over 25% of the lymph 
flowing through the thoracic duct. Barrowman and colleagues demonstrated an increase 
in lymph flows from the intestine and liver in cirrhotic animals by threefold and 30-fold, 
respectively, over values obtained from control animals. They also demonstrated a good 
correlation between intestinal and liver lymph flows and portal venous pressure [60]. In 
portal hypertension, compensatory lymphangiogenic response may initially help to reduce 
the high portal pressure. Oikawa and colleagues used a morphometric analysis to examine 
portal hypertensive-associated changes in lymph vessels and branches of the portal vein, 
with use of immunohistochemical staining for alpha smooth muscle actin, and quantitated 
these changes using an image analysis system. They obtained wedge liver biopsies from 
10 patients with advanced portal hypertension and 10 control samples from patients with 
gastric carcinoma without liver disease. They showed that the proliferation of lymph vessels 
were higher in portal hypertension samples compared to the control samples. On the other 
hand, the number of portal vein branches in portal hypertension samples was not differ-
ent from control samples. They concluded that these alterations in portal hypertension may 
result in a decrease in portal flow associated with an increase in lymph flow resulting in a 
reduction of the high portal vein pressure in idiopathic portal hypertension [61]. With wors-
ening liver fibrosis and ongoing portal hypertension, the lymphatic system fails, resulting in 
buildup of interstitial fluids and ascites formation [55].
6. Renal response
The systemic vasodilation in patients with cirrhosis leads to under filling of arterial vascular 
space and that leads to systemic hypotension. Consequently, baroreceptor-mediated activa-
tion of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system 
(SNS) and nonosmotic release of antidiuretic hormone (ADH) occur to restore normal hemo-
dynamics. This leads to fluid and sodium retention (Figure 1). Sodium retention is the most 
common abnormality of renal function in patients with cirrhosis and ascites [12, 62, 63]. The 
total amount of sodium retained in patients with cirrhosis is dependent on sodium intake, 
non-renal sodium losses and sodium excreted in the urine. Minimizing sodium intake in cir-
rhotic patients may help control ascites. With ongoing hemodynamic disturbance in cirrhosis, 
the equation tips toward sodium retention. Associated with this is an increase in splanchnic 
permeability that, aided by the changes in oncotic pressure, combines to lead to ascites for-
mation [63]. In the initial phases of the disease, this is compensated by an increase in lymph 
return. In fact, the thoracic duct lymph flow, which in normal conditions is lower than 1 liter 
per day, may increase by several folds. When lymph formation overcomes lymph drainage, 
this also results in ascites formation. As a result, renal vasoconstriction persists and results 
in various degrees of renal impairment. The extreme effect would result in severe renal fail-
ure with elevation of blood urea nitrogen and serum-creatinine concentration. The associ-
ated hyponatremia in portal hypertensive ascites carries a bad prognostic value and has been 
linked to mortality [64].
Refractory ascites refers to ascites that cannot be resolved by dietary sodium restriction and 
diuretic treatment. The severity of renal sodium retention increases with the progression of 
Ascites - Physiopathology, Treatment, Complications and Prognosis22
MECHANISM OF ASCITES
Intrahepatic resistance due to
ongoing inflammation
Intrahepatic vascular pressure









Baroreceptor-mediated activation of 
1- Renin-angiotensin-aldosterone system (RAAS)
2-Sympathetic nervous system 
3- Antidiuretic hormone (ADH)
Renal
Vasoconstriction
Sodium and water retention
Ascites Formation
Figure 1. The cascade of changes leading to ascites formation.
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the underlying liver disease and associated portal and systemic hemodynamic disturbance. 
The ongoing activation of the various neurohumoral pathways leads to aggressive renal reab-
sorption of sodium and water. Activation of the neurhormonal pathway also leads to a reduc-
tion in the glomerular filtration rate (GFR) and subsequently leads to a decline in the renal 
function. The enhanced sodium reabsorption at the proximal convoluted tubule leads to a 
significant reduction in the sodium reaching the distal segments of the nephron. This explains 
the failure of loop diuretics and antimineralocorticoid in treating these patients as they work 
predominantly at the distal segments of the nephron. Thus, renal sodium retention mainly 
occurs proximally to the site of action of both antimineralocorticoid and loop diuretics, and 
this can explain why diuretic treatment becomes unsuccessful in some patients. Furthermore, 
when cirrhosis progresses and the arterial vasodilation becomes more marked, the heart can 
no longer keep pace with the marked systemic vasodilatation. This results in an increase in 
the production of endogenous vasoactive compounds, which further increases sodium and 
water retention as a result of this physiological response to the relative arterial underfilling 
[63, 64]. This increased sodium and water retention contributes to increasing ascites, and in 
many cases, to the development of refractory ascites and type 2 HRS. Kraq and colleagues 
investigated the relation between cardiac and renal function in patients with cirrhosis and 
ascites and the impact of cardiac systolic function on survival. Cardiac function was inves-
tigated by gated myocardial perfusion imaging for assessment of cardiac index and cardiac 
volumes. Renal function was assessed by determination of GFR and renal blood flow, and the 
patients were followed up for 12 months. They demonstrated that patients with a low CI had 
a lower GFR and a higher creatinine level. The number of patients who developed type 1 HRS 
within 3 months was significantly higher in the group with low CI than that in the group with 
high CI. They also showed that patients with the lowest CI had significantly poorer survival 
at 3, 9, and 12 months than did those with a higher CI [65].
7. Clinical implications
This circulatory dysfunction in cirrhosis is the proposed pathophysiological mechanism lead-
ing to sodium and water retention in patients with liver cirrhosis. Treatment aimed at revers-
ing this pathophysiological process would likely result in improving the outcome. Albumin 
has been used in clinical trials as a volume expander and, when given with a vasoconstrictor, 
has been shown to improve renal function in the setting of cirrhotic ascites. Martín-Llahí and 
colleagues randomized 46 patients with cirrhosis and HRS to receive terlipressin, a vasopres-
sin analog, and albumin (n = 23) or albumin alone (n = 23) for a maximum of 15 days. They 
monitored renal function closely during the study period. Improvement of renal function 
occurred in 10 patients (43.5%) treated with terlipressin and albumin compared with that 
in two patients (8.7%) treated with albumin alone (P = .017) [66]. Similarly, Guevara and 
colleagues treated 16 patients with HRS with a combination of ornipressin, a potent vaso-
constrictor agent, and albumin to improve the cardiovascular dysfunction. The combined 
treatment was administered for either 3 or 15 days (eight patients each). The shorter treat-
ment duration was associated with normalization of the overactivity of renin-angiotensin 
and sympathetic nervous systems, a marked increase in atrial-natriuretic peptide levels, and 
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only a slight improvement in renal function. However, when treatment was administered 
for 15 days outcome was significantly better. Renal function improved dramatically mani-
fested by normalization of serum creatinine associated with an increase in the GFR and a 
persistent suppression in the activity of vasoconstrictor systems [67]. In another study, Ortega 
and colleagues showed that terlipressin therapy reverses HRS, and the effect was augmented 
when coupled with albumin [68]. Patel and colleagues assessed the efficacy of midodrine and 
octreotide as a therapeutic approach to increasing urinary electrolyte-free water clearance 
in advanced cirrhosis. Patients were treated with albumin, midodrine and octreotide within 
the first 24 h. Urinary electrolyte-free water clearance and serum sodium concentration were 
assessed before and 72 h after treatment. The assessments showed a statistically significant 
increase in serum sodium concentration and urinary electrolyte-free water clearance with 
the use of midodrine and octreotide in the treatment of cirrhosis-associated hyponatremia 
[69]. These studies demonstrate the importance of targeting circulatory dysfunction in end-
stage liver disease. A more challenging aspect in managing these patients is the associated 
cirrhotic cardiomyopathy. The development of HRS in the setting of advanced liver disease is 
associated with a drop in the cardiac output, emphasizing the additional role of cirrhotic car-
diomyopathy in the pathogenesis of hepatorenal dysfunction [65]. Other reports suggested a 
possible role of cirrhotic cardiomyopathy in spontaneous bacterial peritonitis [70].
Transjugular intrahepatic portosystemic shunts (TIPS) have been commonly used to treat 
refractory ascites. Following TIPS insertion, a sudden increase in the preload results in further 
hemodynamic disturbance, and therefore, careful cardiovascular evaluation prior to the pro-
cedure is a necessity [71, 72]. The preexisting subclinical diastolic dysfunction becomes clini-
cally obvious with the sudden increase in the right atrial and pulmonary circulation, leading 
to heart failure. In a recent study, Ascha and colleagues investigated if echocardiographic 
and hemodynamic changes at the time of TIPS can provide any prognostic information. After 
evaluating 418 patients, they showed that a change in the right atrial (RA) pressure after TIPS 
predicted long-term mortality [73]. Others showed a possible impact of intra-procedural RA 
pressure on early post-TIPS mortality [74]. Other studies suggested that an E/A ratio of ≤1 was 
predictive of slow ascites clearance and mortality post-TIPS insertion [75, 76].
Liver transplantation results in correction of portal hypertension and reversal of all the patho-
physiological mechanisms that lead to hyperdynamic circulation [77]. We studied the hemo-
dynamics in the immediate post-transplant period and compared patients with alcoholic 
vs. viral cirrhosis. Within the first 24 h, there was a significant decrease in HR and increase 
in MAP; the extent of the change was similar in both groups. The central venous pressure 
(CVP), pulmonary capillary wedge pressure (PCWP), and systemic vascular resistance index 
(SVRI) increased, and changes were more pronounced in the viral group [78]. Navasa and 
colleagues assessed systemic hemodynamics and plasma levels of aldosterone, glucagon and 
plasma renin in 12 patients with advanced cirrhosis before and 2 weeks and 2 months after 
LT. Elevated aldosterone, plasma renin and glucagon levels decreased to near-normal val-
ues 2 weeks after transplantation. This decrease was associated with reversal of the asso-
ciated splanchnic and systemic vasodilation and restoration of normal hemodynamics [79]. 
Following LT, the rapid reversal of systemic vasodilatation and the associated increase in 
blood pressure exposes the previously subclinical cirrhotic cardiomyopathy. Cardiovascular 
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complications are a major cause of postoperative morbidity and mortality after liver trans-
plantation [80]. Fouad and colleagues reviewed 197 liver transplant recipients for post-liver 
transplant-related cardiac complications. Eighty-two patients suffered one or more cardiac 
complications within 6 months after LT. Pulmonary edema was the most common complica-
tion, occurring in 61 patients; other complications included heart failure (7 patients), arrhyth-
mia (13 patients), pulmonary hypertension (7 patients), pericardial effusion (2 patients), and 
cardiac thrombus formation (1 patient). In their study, cardiac causes were the leading cause 
of death (23.8% of all mortality) [81].
LT induces significant cardiovascular stress. Predicting the development of postoperative 
cardiac complications is very difficult. Two-dimensional and dobutamine stress echocardiog-
raphy were utilized to predict the development of adverse cardiac events following liver 
transplantation, and both had a low predictive value [82]. More recently, a study utilizing 
dobutamine stress perfusion, which provides an assessment of both regional systolic and 
diastolic function as well as microvascular perfusion, revealed a better prediction of post-
transplant cardiac outcome [83]. Management at the time of liver transplantation should 
involve careful fluid management. Immediate postoperative care should include continuous 
cardiac and hemodynamic monitoring and early detection of any potential arrhythmia or any 
other cardiac complication.
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